Search results: Found 9

Listing 1 - 9 of 9
Sort by
New Therapies and Immunological Findings in Melanoma and Other Skin Cancers

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889457120 Year: Pages: 137 DOI: 10.3389/978-2-88945-712-0 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General) --- Allergy and Immunology --- Oncology
Added to DOAB on : 2019-01-23 14:53:43
License:

Loading...
Export citation

Choose an application

Abstract

New therapies are currently being developed in the field of skin cancer. In particular, advances in melanoma now represent the frontline of cancer immunotherapy, as immunological findings in the disease have led to the development of highly effective immune-checkpoint inhibitors. However, these immune-checkpoint inhibitors are only effective in a subset of patients, and may not work in other skin cancer types, thus highlighting the need for further innovation in the field of skin cancer treatment.The purpose of this Research Topic is therefore to provide an up-to-date overview of immune processes and new therapies for melanoma and other skin cancers in order to further stimulate the development of new and even more successful treatments.

Biology-Driven Targeted Therapy of Pediatric Soft-Tissue and Bone Tumors: Current Opportunities and Future Challenges

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889198191 Year: Pages: 147 DOI: 10.3389/978-2-88919-819-1 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General)
Added to DOAB on : 2016-01-19 14:05:46
License:

Loading...
Export citation

Choose an application

Abstract

Recent advances in the understanding of the biological basis of pediatric soft-tissue and bone tumors, especially owing to the advent of “omics” technologies, have led to an exponential increase in the current knowledge on the genetic and cellular patho-mechanisms that drive these diseases. This offers the unprecedented opportunity to develop and implement targeted therapies such as monoclonal antibodies, small molecules, oncolytic viruses, and immunotherapies in standard and/or personalized treatment regimens. However, to date only a few examples document a successful translation of discoveries from the bench to the bedside. Recent international expert congresses such as the “Pediatric Cancer Translational Genomics” conference (Phoenix, Arizona, 2012), the ESF-EMBO workshop on “Molecular Biology and Innovative Therapies in Sarcomas” (Pultusk, Poland, 2012), and the AACR special meeting on “Pediatric Cancer at the Crossroads – Translating Discovery into Improved Outcomes” (San Diego, California, 2013) further emphasize the urgent need for a more rapid and especially more successful translational process. Hence, we strongly believe that a Frontiers Research Topic aiming at this aspect would fit just in time and that it would have great potential to receive numerous contributions of outstanding experts of the field. The proposed Frontiers Research Topic shall provide a platform for active and interdisciplinary discussion, summarize current state-of-the-art knowledge on all basic research and translational aspects in pediatric soft-tissue and bone tumors, and offer new perspectives of how to further promote and accelerate the translational process. We welcome high-quality original research articles, brief reports, as well as opinion, hypothesis, and review articles, and especially encourage submissions from early-career scientists.

Drug-Diagnostics Co-Development in Oncology

Author:
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889193325 Year: Pages: 111 DOI: 10.3389/978-2-88919-332-5 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General) --- Therapeutics --- Science (General)
Added to DOAB on : 2016-03-10 08:14:32
License:

Loading...
Export citation

Choose an application

Abstract

The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. This Research Topic on Drug-Diagnostic Co-Development in Oncology aims to provide you with an insight into some of the diverse activities that constitute this new research area.

Global Challenges in Radiation Oncology

Author:
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889195909 Year: Pages: 66 DOI: 10.3389/978-2-88919-590-9 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General)
Added to DOAB on : 2016-03-10 08:14:32
License:

Loading...
Export citation

Choose an application

Abstract

In the United States, much of the research is focused on developing new and very expensive technologies and drugs - often without a major therapeutic benefit. In resource limited countries, basic oncology care is frequently lacking. In addition, the benefits of various chemo-radiotherapy combinations for a number of malignancies are unknown as these populations have not been adequately investigated. For oncologists in these countries who have marginal to adequate resources, accrual to clinical trials is virtually non-existent to minimal, due to the complexities of their population and competing co-morbidities. As a result, there is a tremendous disparity in treatment outcomes for these populations, compared to those in developed countries. Therefore, we have asked a number of oncologists from different parts of the world to report their experience. Topics that will be covered include locally advanced breast and cervical cancer (India, South Africa), human resources for cancer control in India, systematic review of radiation resources in low and middle income countries, planning national radiotherapy services, building sustainable partnerships through the newly formed ICEC (International Cancer Export Corps), cancer disparities among American Indians, and training radiation oncologists in these under served parts of the world. Authors will discuss "lessons learned" from their populations, practical suggestions to address these disparities, and how we as a global oncology community can address, and mitigate these global challenges. The editorial by Dr. Coleman and myself highlights the invaluable contributions from our global contributors. Thank you for taking the time to read this special issue on global cancer disparities. We are all energized to begin addressing the needs of our cancer patients worldwide.

Psychosocial Advances in Neuro-Oncology

Authors: --- ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889197828 Year: Pages: 142 DOI: 10.3389/978-2-88919-782-8 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General)
Added to DOAB on : 2016-04-07 11:22:02
License:

Loading...
Export citation

Choose an application

Abstract

Neuro-oncology is a rapidly growing field concerned with scientific developments and clinical applications related to neuroscience, neuropsychology, cancer and oncology. Neuro-oncological disorders include cancers that directly affect the central nervous system (CNS), such as brain tumours and brain metastases, and non-CNS cancers with treatments that produce neurocognitive impairment. To date, the biological mechanisms and neuropsychological effects of brain tumour and cancer have been the dominant focus in neuro-oncology literature. In terms of psychosocial aspects of care, people’s understanding of their diagnosis and symptoms and how they cope with their illness has a major influence on their emotional well-being and quality of life.The development and evaluation of psychological and supportive care interventions for people with brain tumour is an area of emerging research and of high interest to health professionals working in the field. This Research Topic aims to enhance understanding of the psychological and social consequences of brain tumour and other cancers impacting neurocognitive function. It also aims to showcase new developments in assessment and psychosocial intervention approaches.

Cardiovascular Toxicities of Breast Cancer Treatment: Emerging Issues in Cardio-Oncology

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889195695 Year: Pages: 83 DOI: 10.3389/978-2-88919-569-5 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General)
Added to DOAB on : 2017-02-03 17:04:57
License:

Loading...
Export citation

Choose an application

Abstract

Cancer and cardiovascular disease (CVD) are the two most common causes of mortality and morbidity worldwide. The incidence of both cancer and cardiovascular disease increases with age. With increased life expectancy, the burden of both these diseases will increase substantially in coming years. Patients with CVD share multiple common risk factors and lifestyle behaviors in addition to frequently suffering from multiple comorbid conditions. Tobacco use, hypertension, high cholesterol, diabetes, physical inactivity, and poor nutrition are all established risk factors of heart disease. Patients with diseases such as breast cancer may develop CVD from treatment, such as use of chemotherapy and RT. Effects on the heart are a potentially significant and serious clinical problem in radiation therapy treatment of breast cancer. Over the course of the past 50 years, there have been great advances in the delivery of RT due to the development of new techniques, beam energy, improvement in imaging modalities, and development of image registration strategies. It is hypothesized that cardiac damage from RT is correlated to the dose absorbed by the heart and differs between left- and right-breast radiotherapy. The damage to cardiac micro- and macro-vasculature is the pathophysiological cause of RT-related heart disease. Given the growing clinical relevance of cardio-oncology, this Frontiers in Oncology Research Topic provides a venue for disseminating focused reviews and cutting edge research in this quickly growing field. We encourage submission of original papers and reviews dealing with cardiac toxicity after breast cancer treatment, motion management to reduce cardiac exposure, imaging to evaluate potential cardiac toxicities and primary prevention of cardiac disease in the breast cancer patient.

Data-Based Radiation Oncology - Design of Clinical Trials

Authors: --- --- --- --- et al.
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889454389 Year: Pages: 109 DOI: 10.3389/978-2-88945-438-9 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General) --- Oncology
Added to DOAB on : 2018-11-16 17:17:57
License:

Loading...
Export citation

Choose an application

Abstract

In radiation oncology as in many other specialties clinical trials are essential to investigate new therapy approaches. Usually, preparation for a prospective clinical trial is extremely time consuming until ethics approval is obtained. To test a new treatment usually many years pass before it can be implemented in the routine care. During that time, already new interventions emerge, new drugs appear on the market, technical & physical innovations are being implemented, novel biology driven concepts are translated into clinical approaches while we are still investigating the ones from years ago. Another problem is associated with molecular diagnostics and the growing amount of tumor specific biomarkers which allows for a better stratification of patient subgroups. On the other side, this may result in a much longer time for patient recruiting and consequently in larger multicenter trials. Moreover, all of the relevant data must be readily available for treatment decision making, treatment as well as follow-up, and ultimately for trial evaluation. This challenges even more for agreed standards in data acquisition, quality and management. How could we change the way currently clinical trials are performed in a way they are safe and ethically justifiable and speed up the initiation process, so we can provide new and better treatments faster for our patients?Further, while we rely on various quantitative information handling distributed, large heterogeneous amounts of data efficiently is very important. Thus data management becomes a strong focus. A good infrastructure helps to plan, tailor and conduct clinical trials in a way they are easy and quickly analyzable.In this research topic we want to discuss new ideas for intelligent trial designs and concepts for data management.

Precision Medicine in Oncology

Authors: --- --- ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889457052 Year: Pages: 163 DOI: 10.3389/978-2-88945-705-2 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General) --- Oncology
Added to DOAB on : 2019-01-23 14:53:43
License:

Loading...
Export citation

Choose an application

Abstract

The emerging precision medicine approach aims to tailor disease prevention and treatment to each patient on the basis of individual variability, environmental factors and lifestyle. Fundamental achievements in the last few decades have converged to offer nowadays the compelling opportunity to move towards this innovative approach: i) unprecedented improvements in disease modeling in silico, in vitro and in vivo; ii) acquisition of a wide range of biomedical information combined with the development of computational toolsets for flexible and integrative analyses of multi-assay datasets. Our deeper understanding of oncogenic mechanisms has finally begun to have a crucial impact on clinical decisions at several steps, from cancer prevention and diagnosis to therapeutic intervention. However, precision oncology still encounters several unresolved hurdles including tumour heterogeneity and recurrence as well as unexplained drug resistance and lack of effective ways to monitor response to therapeutic treatments. Notably, limitations in biomedical research regulation and governance represent additional debatable issues that need careful consideration.

Machine Learning With Radiation Oncology Big Data

Authors: --- ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889457304 Year: Pages: 146 DOI: 10.3389/978-2-88945-730-4 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General) --- Oncology
Added to DOAB on : 2019-01-23 14:53:43
License:

Loading...
Export citation

Choose an application

Abstract

Radiation oncology is uniquely positioned to harness the power of big data as vast amounts of data are generated at an unprecedented pace for individual patients in imaging studies and radiation treatments worldwide. The big data encountered in the radiotherapy clinic may include patient demographics stored in the electronic medical record (EMR) systems, plan settings and dose volumetric information of the tumors and normal tissues generated by treatment planning systems (TPS), anatomical and functional information from diagnostic and therapeutic imaging modalities (e.g., CT, PET, MRI and kVCBCT) stored in picture archiving and communication systems (PACS), as well as the genomics, proteomics and metabolomics information derived from blood and tissue specimens. Yet, the great potential of big data in radiation oncology has not been fully exploited for the benefits of cancer patients due to a variety of technical hurdles and hardware limitations.With recent development in computer technology, there have been increasing and promising applications of machine learning algorithms involving the big data in radiation oncology. This research topic is intended to present novel technological breakthroughs and state-of-the-art developments in machine learning and data mining in radiation oncology in recent years.

Listing 1 - 9 of 9
Sort by
Narrow your search

Publisher

Frontiers Media SA (9)


License

CC by (9)


Language

english (9)


Year
From To Submit

2019 (3)

2018 (1)

2016 (3)

2015 (1)

2014 (1)